

Nectar Lifesciences Ltd.



Ref.: NLL/CS/2025-468

March 13, 2025

To

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Update on EU regulatory inspection and Business Status.

Ref: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015.

Dear Sir/ Madam,

Following our earlier disclosure vide letter no. NLL/CS/2025-467 dated March 10, 2025 regarding the inspection of our manufacturing facility by the European Directorate for the Quality of Medicines, we would like to provide an update on the matter.

The management is fully aware of the seriousness of the situation and is taking all necessary steps to ensure that we are back on track. As part of our growth strategy, we consider all geographies, including the EU, as key markets. We would like to reaffirm our commitment to undertaking the required remediation on an urgent basis to maintain business continuity in the EU. The European market contributes 2.7% to our total API sales.

The observations from the inspection are being addressed through a structured Corrective Action and Preventive Action (CAPA) plan, reflecting our unwavering commitment to compliance and quality assurance. We continue to engage proactively with regulatory authorities and will provide further updates as required. Our focus remains on upholding high standards and ensuring sustainable growth.

Kindly take the same on record and oblige.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Amit Chadah)

Chief Executive Officer